e past year, Advanced Cell Technology has made significant
progress in its RPE (retinal pigment epithelium) and its HG (hemangioblast)
programs to treat degenerative retinal disorders and cardiovascular
disease, and expects to file INDs for both programs by the end of 2008.
Furthermore, the company announced last month that it had entered into a
definitive merger agreement to acquire autologous adult stem cell company
Mytogen, Inc. and its Myoblast Program for the treatment of heart failure.
Mytogen has successfully completed Phase I clinical trials and will begin
Phase II trials after the merger with ACT. Upon the transaction's closing,
Advanced Cell Technology will transition from a development stage to a
clinical stage company.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying
embryonic stem cell technology in the emerging field of regenerative
medicine. The company operates facilities in Alameda, California and
Worcester, Massachusetts.
For more information, visit http://www.advancedcell.com
Forward-Looking Statements
Statements in this news release regarding future financial and
operating results, future growth in research and development programs,
potential applications of our technology, opportunities for the company and
any other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Any statements that are not statements of historical fact (including
statements containing the words "will," "believes," "plans," "anticipates,"
"expects," "estimates," and similar expressions) should also be considered
to be forward-looking statements. There are a number of important factors
that could cause actual results or events to differ materially from those
indicated by such
'/>"/>
SOURCE Advanced Cell Technology, Inc. Copyright©2007 PR Newswire.All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Achieving Reliable Protein Quantitation Results Using ICAT Reagents, MALDITOF Mass Spectrometry, and Advanced Data Interpretation Tool2.
Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option3.
384 Well Pipetting Precision and Accuracy Testing Using the Sciclone Advanced Liquid Handler4.
WARF expands license agreement with Advanced Cell Technology5.
Rockwells $1M gift to UWM will support advanced automation research6.
Advanced CIO: Technology execs must trumpet their success7.
FDA approves advanced digital mammography system8.
Tech Digest: Inacom; St. Michaels, St. Clares hospitals; Merge eMed; Advanced Data-Comm; Blue Cross and Blue Shield9.
Wisconsins insurance companies use advanced IT to speed relief10.
$60 Million Available in Advanced Tech Competition11.
Advanced Life Sciences to Hit the Road For $30 Million in Funding